公開日期 | 標題 | 作者 | 來源出版物 | scopus | WOS | 全文 |
2020 | Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1–2 trials | Drilon A.; Siena S.; Dziadziuszko R.; Barlesi F.; Krebs M.G.; Shaw A.T.; de Braud F.; Rolfo C.; Ahn M.-J.; Wolf J.; Seto T.; Cho B.C.; Patel M.R.; Chiu C.-H.; John T.; Goto K.; Karapetis C.S.; Arkenau H.-T.; Kim S.-W.; Ohe Y.; Li Y.-C.; Chae Y.K.; Chung C.H.; Otterson G.A.; Murakami H.; CHIA-CHI LIN ; Tan D.S.W.; Prenen H.; Riehl T.; Chow-Maneval E.; Simmons B.; Cui N.; Johnson A.; Eng S.; Wilson T.R.; Doebele R.C. | The Lancet Oncology | 326 | 250 | |
2016 | First-line erlotinib therapy until and beyond response evaluation criteria in solid tumors progression in Asian patients with epidermal growth factor receptor mutation-positive non-small-cell lung cancer the ASPIRATION study | Park K.; CHONG-JEN YU ; Kim S.-W.; Lin M.-C.; Sriuranpong V.; Tsai C.-M.; Lee J.-S.; Kang J.-H.; Chan K.C.A.; Perez-Moreno P.; Button P.; Ahn M.-J.; Mok T. | JAMA Oncology | 200 | 164 | |
2014 | First-line pemetrexed plus cisplatin followed by gefitinib maintenance therapy versus gefitinib monotherapy in East Asian patients with locally advanced or metastatic non-squamous non-small cell lung cancer: A randomised, phase 3 trial | CHIH-HSIN YANG ; Kang J.H.; Mok T.; Ahn M.-J.; Srimuninnimit V.; CHIA-CHI LIN ; Kim D.-W.; Tsai C.-M.; Barraclough H.; Altug S.; Orlando M.; Park K. | European Journal of Cancer | 41 | 40 | |
2019 | Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial | Kato K.; Cho B.C.; Takahashi M.; Okada M.; Lin C.-Y.; Chin K.; Kadowaki S.; Ahn M.-J.; Hamamoto Y.; Doki Y.; Yen C.-C.; Kubota Y.; Kim S.-B.; CHIH-HUNG HSU ; Holtved E.; Xynos I.; Kodani M.; Kitagawa Y. | The Lancet Oncology | 735 | 630 | |
2020 | Osimertinib in patients with T790M-positive advanced non-small cell lung cancer: Korean subgroup analysis from phase II studies | Ahn M.-J.; Han J.-Y.; Kim D.-W.; Cho B.C.; Kang J.-H.; Kim S.-W.; CHIH-HSIN YANG ; Mitsudomi T.; Lee J.S. | Cancer Research and Treatment | 5 | 5 | |
2017 | Osimertinib in pretreated T790M-positive advanced non-small-cell lung cancer: AURA study phase II extension component | CHIH-HSIN YANG ; Ahn M.-J.; Kim D.-W.; Ramalingam S.S.; Sequist L.V.; Su W.-C.; Kim S.-W.; Kim J.-H.; Planchard D.; Felip E.; Blackhall F.; Haggstrom D.; Yoh K.; Novello S.; Gold K.; Hirashima T.; Chia-Chi Lin ; Mann H.; Cantarini M.; Ghiorghiu S.; Jänne P.A. | Journal of Clinical Oncology | 459 | 443 | |
2020 | Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study | Sequist L.V.; Han J.-Y.; Ahn M.-J.; Cho B.C.; Yu H.; Kim S.-W.; CHIH-HSIN YANG ; Lee J.S.; Su W.-C.; Kowalski D.; Orlov S.; Cantarini M.; Verheijen R.B.; Mellemgaard A.; Ottesen L.; Frewer P.; Ou X.; Oxnard G. | The Lancet Oncology | 298 | 252 | |
2017 | A systematic review and meta-analysis of individual patient data on the impact of the BIM deletion polymorphism on treatment outcomes in epidermal growth factor receptor mutant lung cancer | Soh S.X.; Siddiqui F.J.; Allen J.C.; Kim G.W.; Lee J.C.; Yatabe Y.; Soda M.; Mano H.; Soo R.A.; Chin T.-M.; Ebi H.; Yano S.; Matsuo K.; Niu X.; Lu S.; Isobe K.; JIH-HSIANG LEE ; CHIH-HSIN YANG ; Zhao M.; Zhou C.; Lee J.-K.; Lee S.-H.; Lee J.Y.; Ahn M.-J.; Tan T.J.; Tan D.S.; Tan E.-H.; Ong S.T.; Lim W.-T. | Oncotarget | 14 | 12 | |
2020 | TATTON: a multi-arm, phase Ib trial of osimertinib combined with selumetinib, savolitinib, or durvalumab in EGFR-mutant lung cancer | Oxnard G.R.; CHIH-HSIN YANG ; Yu H.; Kim S.-W.; Saka H.; Horn L.; Goto K.; Ohe Y.; Mann H.; Thress K.S.; Frigault M.M.; Vishwanathan K.; Ghiorghiu D.; Ramalingam S.S.; Ahn M.-J. | Annals of Oncology | 282 | 228 | |
2022 | Three-Year Follow-Up and Response-Survival Relationship of Nivolumab in Previously Treated Patients with Advanced Esophageal Squamous Cell Carcinoma (ATTRACTION-3) | Okada M.; Kato K.; Cho B.C.; Takahashi M.; Lin C.-Y.; Chin K.; Kadowaki S.; Ahn M.-J.; Hamamoto Y.; Doki Y.; Yen C.-C.; Kubota Y.; Kim S.-B.; CHIH-HUNG HSU ; Holtved E.; Xynos I.; Matsumura Y.; Takazawa A.; Kitagawa Y. | Clinical Cancer Research | 25 | 16 | |